EMA Begins Setting Up New Bodies To Tackle Drug Shortages
Workshop To Be Held To Explain Agency's Expanded Role
Executive Summary
A new EU regulation has come into effect, giving the European Medicines Agency wider powers to monitor, prevent and manage shortages of medicines and medical devices in public health emergencies. A number of steering groups and other bodies and networks are being set up to put the new systems into action.
You may also be interested in...
Coronavirus Notebook: Global COVID-19 Summit To Press For More Funding For Vaccines & Treatments, WHO Calls For End To IP Waiver ‘Stalemate’
CEPI has announced funding for a “variant-proof” vaccine being developed by a multidisciplinary consortium. The European Medicines Agency's new committee on drug shortages in health crises has held its first meeting, and the European Parliament’s new COVID-19 committee will quiz the health commissioner on the EU’s vaccines strategy and response to the pandemic.
New EU Body To Deal With COVID-19 Vaccine Strategy & Procurement
Europe is stepping up its efforts to prepare for future health crises. A new parliamentary committee will look at how to make the most of the lessons learned from the coronavirus pandemic, while EU health ministers will next week discuss “vaccine solidarity” and the draft regulation on cross-border threats to health.
EMA’s New Emergency Task Force Gets ‘Balanced’ COVID-19 Expertise
The task force, which is a key component of the European Medicines Agency’s extended mandate, will include experts in the fields of vaccinology, antivirals, clinical trials, immunology and immunotherapy.